Skip to main content

A new target for treating bone marrow disorders

Advertisement

Patients with myeloproliferative neoplasms (MPN), a group of malignant bone-marrow disorders, often harbour a cancer-causing, mutated form of the calreticulin (CALR) gene. This specific type of blood cancer is characterised by increased production of blood cells, a susceptibility to thrombosis and frequent progression to acute leukaemia. Scientists from Robert Kralovics’ research group at CeMM (Centre for Molecular Medicine of the Austrian Academy of Sciences) have now identified haematoxylin as a novel CALR inhibitor. Haematoxylin is used in histological staining procedures.

Back in 2013, the same laboratory discovered that these patients frequently carried carcinogenic mutations in the gene, which are now used as medical markers. The mechanism by which these mutations can lead to leukaemia has also been identified. The cancer-causing effect of the mutations is underpinned by the interaction between CALR’s N-glycan-binding domain and the thrombopoietin receptor. Now, the study’s lead author, Ruochen Jia, has shown that a group of chemicals, foremost among them haematoxylin, can selectively kill mutated CALR cells. The findings thus provide valuable insights into potential treatment approaches for myeloproliferative neoplasms

“Our study demonstrates the enormous therapeutic potential of CALR inhibitor therapy,” explains Kralovics. “The treatment of patients with primary myelofibrosis (PMF) continues to yield poor clinical outcomes. They are most likely to develop acute myeloid leukaemia. As around one third of PMF patients have a CALR mutation, they could benefit particularly from this new therapeutic approach.”

References:
CeMM, MedUni Vienna: Hematoxylin binds to mutant calreticulin and disrupts its abnormal interaction with the thrombopoietin receptor, Blood, 17 November 2020; DOI: https://doi.org/10.1182/blood.2020006264

  • Author

    Gernot Hofer

More on this topic
Hormones

Low testosterone in men: symptoms, causes and treatment

Fatigue, a reduced sex drive, and a lack of energy: these symptoms can have many causes. One possible explanation is a testosterone deficiency. However, it is not possible to determine whether testosterone levels are actually too low based solely on the symptoms or on a single blood test result.

Men's health
Men's health

PSA level: What does it mean, and when is it too high?




The PSA level is one of the best-known laboratory test results relating to the prostate. Many men come across it for the first time during a screening examination or when having symptoms investigated. An abnormal result often raises questions: Is this already a sign of prostate cancer? What levels are considered normal?

Prostate
Pollen allergy

The right diet for hay fever

Anyone suffering from hay fever should pay particular attention to their diet so as not to make the symptoms any worse.

Nutrition
Urology

Prostate health: What men need to know

The prostate is a gland in a man’s body that is only the size of a chestnut, but it plays a crucial role in well-being, urinary function and male sexuality. Benign enlargement and prostate cancer become more common in older age.

Prostate